AbbVie Inc. has received Health Canada approval for MAVIRET® (glecaprevir/pibrentasvir tablets) for the treatment of both acute and chronic hepatitis C virus (HCV) infection in adults and pediatric patients aged 3 years and older and weighing at least 12 kg. MAVIRET is now the first and only oral eight-week pan-genotypic treatment option approved in Canada for HCV. The approval, granted through Health Canada’s Priority Review process, was based on data from the Phase 3 M20-350 Study demonstrating high efficacy in treating acute hepatitis C. This regulatory milestone supports efforts to enhance early detection and treatment of HCV, aligning with the World Health Organization’s goal of eliminating hepatitis C as a public health concern by 2030.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AbbVie Inc. published the original content used to generate this news brief via CNW (Ref. ID: C9907) on January 06, 2026, and is solely responsible for the information contained therein.